Prelude Therapeutics boosts IPO proceeds target to up to $158M

The company is poised to become the fifth Philadelphia-area life sciences companies to go public this year through an IPO.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.